Thus, irrespective of the mechanism, the profound anti-steatotic effects of amlexanox seen in mouse models of MAFLD and MASH are likely to prevent subsequent mitochondrial dysfunction, thus obscuring the potential effects of TBK1 inhibition on mitochondrial quality control. The gene discussed is TBK1; the disease is metabolic dysfunction-associated steatohepatitis.